Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Omeros is a commercial-stage biotechnology company focused on complement-mediated diseases, cancers, and addictive disorders. The quarter marks the first full period of commercial sales for its lead product, YARTEMLEA (narsoplimab), following FDA approval in December 2025 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The company also completed the sale of its zaltenibart program to Novo Nordisk in late 2025.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Product Sales, Net | $9,893 | $0 |
| Cost of Product Sales | $587 | $0 |
| Gross Profit | $9,306 | $0 |
| Research & Development (R&D) | $13,358 | $23,846 |
| Selling, General & Administrative (SG&A) | $13,369 | $11,123 |
| Loss from Operations | $(17,421) | $(34,969) |
| Net Gain on Fair Value of Financial Instruments | $73,146 | $(65) |
| Net Income (Loss) | $56,060 | $(33,460) |
| Diluted EPS | $0.62 | $(0.58) |
| Cash and Cash Equivalents | $1,906 | $4,261 |
| Short-term Investments | $133,410 | $162,144 |
| Total Liquidity (Cash + ST Investments) | $135,316 | $166,405 |
| Net Cash Used in Operating Activities | $(14,506) | $(35,841) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $9.9 million in product sales for the first time, driven by the January 2026 launch of YARTEMLEA. This contrasts with zero product revenue in Q1 2025.
- Net Income Volatility: Net income swung from a loss of $33.5 million in Q1 2025 to a profit of $56.1 million in Q1 2026. This is primarily attributable to a $73.1 million non-cash gain on the remeasurement of the embedded derivative associated with the 2029 Convertible Notes, rather than core operational profitability.
- Expense Reduction: R&D expenses decreased by $10.5 million ($23.8M to $13.4M) due to the divestiture of the zaltenibart program to Novo Nordisk. SG&A expenses increased by $2.2 million due to the build-out of the commercial organization for YARTEMLEA.
- Debt Repayment: The company repaid the remaining $17.1 million principal balance of its 2026 Notes at maturity in February 2026. The Term Loan of $67.1 million was repaid in November 2025.
Guidance, Outlook, and Risks
- Commercial Outlook: Management expects SG&A and R&D expenses to increase in Q2 2026 due to expanded marketing activities for YARTEMLEA and continued investment in the OncotoX-AML and lectin pathway programs. The company is evaluating partnerships for ex-U.S. commercialization of YARTEMLEA.
- Regulatory Status: A Marketing Authorization Application (MAA) for YARTEMLEA has been submitted to the European Medicines Agency (EMA). The company is targeting the initiation of an in-patient clinical trial for its PDE7 inhibitor (OMS527) by year-end 2026.
- Liquidity: As of March 31, 2026, the company held $135.3 million in cash and short-term investments. Management expects this, combined with future YARTEMLEA sales, to fund operations for more than 12 months.
- Key Risks:
- Derivative Volatility: The company's reported net income is heavily influenced by the fair value of the embedded derivative on its 2029 Notes. A 20% swing in stock price could result in a $23.8 million change in the derivative's fair value.
- Commercial Execution: Revenue estimates for YARTEMLEA are subject to significant judgment regarding chargebacks, returns, and wholesaler distribution fees, given the limited commercial history.
- OMIDRIA Royalty Obligation: The company has a significant royalty obligation ($161.8 million) related to the sale of OMIDRIA, which is remitted to DRI Healthcare Acquisition LP.
Investor Verification Checklist
- Derivative Impact: Verify the sensitivity of the $73.1 million non-cash gain to stock price fluctuations and confirm that core operating cash flow remains negative despite the reported net income.
- YARTEMLEA Adoption: Monitor the number of unique accounts ordering YARTEMLEA (30 as of March 31) and the trajectory of gross-to-net deductions (chargebacks and fees) as commercial data matures.
- Debt Structure: Confirm the terms of the remaining 2029 Notes ($70.8 million principal), including the conversion price ($6.18) and the potential for dilution or cash settlement.
- OMIDRIA Cash Flow: Review the roll-forward of the OMIDRIA contract royalty asset and obligation to understand the timing and magnitude of future royalty pass-through payments to DRI.
- Capital Allocation: Track the utilization of the $100 million share repurchase program (approx. $95.9 million remaining) and the $150 million ATM facility.